Topical chlormethine gel in the treatment of mycosis fungoides: A single‐center real‐life experience and systematic review of the literature. Issue 9 (27th July 2022)

• Record Type: Journal Article
• Authors: Laghi, Alessandro; Franceschini, Chiara; Mandel, Victor Desmond; Teoli, Miriam; Musicco, Felice; Sansone, Massimo; La Malfa, Antonia Marina; Ardigò, Marco
• Is Part Of: Dermatologic therapy. Volume 35:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-27
• Subjects: drug‐related side effects and adverse reactions -- lymphoma -- mechlorethamine -- mycosis fungoides -- nitrogen mustard compounds -- cutaneous T‐cell lymphoma; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15683
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Gel formulation of chlormethine (CG) has gained a preeminent role among therapies available for mycosis fungoides (MF). To evaluate the frequency of use of CG for MF treatment and to determine the limits and potentialities of CG in a real‐world setting. A systematic review of articles published prior to October 2021 was performed. Articles were included in the review if a full‐text English version was available. MEDLINE (PubMed), Scopus, and Web of Science were each queried from their date of inception with the following terms: "mechlorethamine gel", "chlormethine gel", and "mycosis fungoides". The reference lists of the studies retrieved were searched manually. Moreover, this study included all consecutive patients with different stages of MF (from IA to IIB) who started treatment with CG gel between July 2020 and May 2021. Data of the literature were compared to our single‐center real‐life experience. Of the surveyed literature, 11 publications were included in the final analysis describing a total of 548 patients with MF. Eleven patients with a median (standard deviation) age of 66 years (15.1) were enrolled and followed up, receiving CG (0.02% chlormethine HCl). Response to treatment resulted higher (90.1%) in our study population than in other real‐world experiences published in literature. This systematic review supports the role of CG for MF treatment, showing its limits and potentialities. Our single‐center real‐life experience revealed an elevated percentage of clinical response with high safety and tolerance, demonstrating its versatile use with dose and application rate adaptability.